Individuals with advanced lung cancer often have other comorbid conditions, and many may be on complex, costly, and even inappropriate medication regimens. A new British Journal of Clinical Pharmacology study examined the extent to which such patients are prescribed medications with questionable benefit.
In an analysis of information from two centers in the United Kingdom and the United States, the use of preventative medicines--drugs for diabetes, hypertension, hyperlipidemia, antiplatelet agents, and vitamins/minerals--was common at hospital admission and discharge for patients who died of lung cancer.
In the UK site (125 people), the average number of preventative medications was 1.9 at admission and 1.7 at discharge, whilst in the US site (191 people) the average was 2.6 at admission and 1.9 at discharge. "There may be scope to develop an intervention that embraces the principles of deprescribing at the point of hospital discharge to reduce inappropriate prescribing in lung cancer patients," the authors wrote.
Peer Reviewed, Retrospective study, Human
Link to Study: https:/
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology contains papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment.
Wiley is a global leader in education and scholarly research. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.